Clinical Trials Browser

INDUSTRY × fludarabine × Genitourinary × Clear all

Glioblastoma, Carcinoma, Hepatocellular, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT07492628 2026-03-25

DUET-UC-NK

Phase 1 Recruiting

42 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04696731 2025-09-25

TRAVERSE

Phase 1 Active not recruiting

120 enrolled

Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT06480565 2025-08-15

A Phase 1/2 Trial of ADI-270 in ccRCC

Phase 1/2 Active not recruiting

60 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT04319757 2024-12-05

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Phase 1 Completed

12 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06505551 2024-07-17

Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma

Phase 1/2 Not yet recruiting

66 enrolled

GastrointestinalGenitourinaryGynecologicHead & Neck

Anus Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT04633148 2024-04-23

Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

Phase 1 Terminated

16 enrolled

Genitourinary

Prostatic Neoplasms

NCT05787535 2024-02-02

HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

Phase 1 Unknown

17 enrolled

GastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Uterine Cervical Neoplasms, Oropharyngeal Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT05952947 2024-02-02

HRYZ-T101 Injection for HPV18 Positive Solid Tumor

Phase 1 Recruiting

32 enrolled

GastrointestinalGenitourinaryGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Uterine Cervical Neoplasms, Penile Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms

NCT04551885 2023-09-21

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

12 enrolled

BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT05069935 2023-09-21

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Phase 1 Terminated

16 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Stomach Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04227275 2023-08-21

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 1 Terminated

16 enrolled

Genitourinary

Prostatic Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Phase 1 Completed

37 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT03692663 2022-08-01

Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer

Phase EARLY_PHASE1 Unknown

9 enrolled

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT04596033 2022-07-15

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Phase 1 Terminated

49 enrolled

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT00625430 2011-07-11

FP253-GDEPT

Phase 1 Unknown

18 enrolled

Genitourinary

Adenoviridae Infections, Prostatic Neoplasms

Clinical Trials

SELECT-2CAR

DUET-UC-NK

TRAVERSE

A Phase 1/2 Trial of ADI-270 in ccRCC

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors

Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma

Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

HRYZ-T101 TCR-T Cell for HPV-18 Positive Advanced Solid Tumor

HRYZ-T101 Injection for HPV18 Positive Solid Tumor

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

FP253-GDEPT